Home DNA Damage/DNA Repair Topoisomerase Inhibitor Topotecan HCl

nur für Forschungszwecke

Topotecan HCl Topoisomerase Inhibitor

Kat.-Nr.: S1231

Topotecan HCl ist ein Topoisomerase I-Inhibitor für MCF-7 Luc-Zellen und DU-145 Luc-Zellen mit einer IC50 von 13 nM bzw. 2 nM in zellfreien Assays. Diese Verbindung induziert Autophagy und Apoptosis.
Topotecan HCl Topoisomerase Inhibitor Chemical Structure

Chemische Struktur

Molekulargewicht: 457.91

Springe zu

Qualitätskontrolle (Quality Control)

Charge: Reinheit: 99.98%
99.98

Zellkultur, Behandlung & Arbeitskonzentration
(Cell Culture, Treatment & Working Concentration)

Zelllinien Assay-Typ Konzentration Inkubationszeit Formulierung Aktivitätsbeschreibung PMID
human MDA-MB-435 cells Cytotoxic assay 72 h Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay, ic50=1 nM 20371183
human Bel7402 cells Cytotoxic assay 96 h Cytotoxicity against human Bel7402 cells after 96 hrs by MTT assay, IC50=1.2 nM 15165144
human HCT8 cells Cytotoxic assay 96 h Cytotoxicity against human HCT8 cells after 96 hrs by MTT assay, IC50=1.5 nM 15165144
human MCF7 cells Cytotoxic assay 96 h Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay, IC50=1.8 nM 15165144
human A549 cells Cytotoxic assay 96 h Cytotoxicity against human A549 cells after 96 hrs by MTT assay, IC50=3.2 nM 15165144
human colon carcinoma SW620 cell Cytotoxic assay Cytotoxic potentiation of Topotecan (TP) by the compound in human colon carcinoma SW620 cell line, IC50=3.2 nM 12408707
human MESSA cells Cytotoxic assay 72 h Cytotoxicity against human MESSA cells after 72 hrs by alamar blue assay, IC50=4 nM 21341674
human BGC823 cells Cytotoxic assay 96 h Cytotoxicity against human BGC823 cells after 96 hrs by MTT assay, IC50=4.3 nM 15165144
human Ketr3 cells Cytotoxic assay 96 h Cytotoxicity against human Ketr3 cells after 96 hrs by MTT assay, IC50=4.9 nM 15165144
LOX cells Cytotoxic assay Cytotoxicity was determined in vitro in LOX cells (melanoma) of human tumor cell lines by using MTT assay, IC50=5 nM 7853331
human A549 cells Function assay 4 h Antitumor activity against human A549 cells after 4 hrs by MTT assay, IC50=5 nM 18207748
human H69 cells Cytotoxic assay 72 h Cytotoxicity against human H69 cells after 72 hrs by alamar blue assay, IC50=6 nM 21341674
human A2780 cells Cytotoxic assay 72 h Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay, IC50=6 nM 22959246
human LNCAP cells Cytotoxic assay 72 h Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50=9 nM 21341674
human HOP62 cells Growth inhibition assay Growth inhibition of human HOP62 cells by five-dose growth inhibition assay, IC50=10 nM 25909279
human MCF7 cells Growth inhibition assay Growth inhibition of human MCF7 cells by five-dose growth inhibition assay, IC50=10 nM 25909279
human UACC62 cells Growth inhibition assay Growth inhibition of human UACC62 cells by five-dose growth inhibition assay, IC50=10 nM 25909279
human DU145 cells Growth inhibition assay Growth inhibition of human DU145 cells by five-dose growth inhibition assay, IC50=10 nM 25909279
LoVo cell line Cytotoxic assay Cytotoxic potentiation of Topotecan (TP) by the compound in (human colorectal cancer LoVo cell line, IC50=11.6 nM 12408707
human lymphoblast tumor cell line RPM18402 Cytotoxic assay Cytotoxicity against human lymphoblast tumor cell line RPM18402, IC50=12 nM 12392745
human HL60 cells Function assay Antitumor activity against human HL60 cells by SRB method, IC50=12 nM 19541483
human A375 cells Cytotoxic assay 72 h Cytotoxicity against human A375 cells after 72 hrs by alamar blue assay, IC50=13 nM 21341674
COR-L23/P cell Cytotoxic assay Cytotoxicity measured using the COR-L23 parental (COR-L23/P) human non small cell lung carcinoma cell line, IC50=13.2 nM 11806724
human NCI-H460 cells Proliferation assay 72 h Antiproliferative activity against human NCI-H460 cells after 72 hrs by coulter counter analysis, IC50=16 nM 21783369
human MOLT4 cells Cytotoxic assay 72 h Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay, IC50=19 nM 24900725
human LoVo cells Cytotoxic assay 72 h Cytotoxicity against human LoVo cells after 72 hrs by MTT assay, IC50=20 nM 20371183
RPM18402 tumor cell line Proliferation assay Concentration required to inhibit cell proliferation in RPM18402 tumor cell line, IC50=20 nM 15482929
human SN12C cells Growth inhibition assay Growth inhibition of human SN12C cells by five-dose growth inhibition assay, GI50=20 nM 25909279
human RPMI8226 cells Cytotoxic assay Cytotoxicity against human RPMI8226 cells by MTT method, IC50=21 nM 19012996
HT-29 cells Cytotoxic assay Cytotoxicity was determined in vitro in HT-29 cells(colon) of human tumor cell lines by using MTT assay, IC50=25 nM 7853331
SK-BR-3 cells Cytotoxic assay In Vitro cytotoxicity against human breast cancer cell line (SK-BR-3), IC50=26 nM 11334569
HeLa cells Growth inhibition assay Growth inhibition of HeLa cells after 4 days, GI50=30 nM 17418582
UACC 62 cells Cytotoxic assay Tested in vitro for cytotoxicity against human tumor cell line UACC 62 (melanoma), GI50=30 nM 10714502
human HCT116 cells Growth inhibition assay Growth inhibition of human HCT116 cells by five-dose growth inhibition assay, GI50=30 nM 25909279
human lung cancer cell line (H128) Cytotoxic assay In Vitro cytotoxicity against human lung cancer cell line (H128), IC50=31 nM 11334569
human MES-SA/Dx5 cells Cytotoxic assay Cytotoxicity against human MES-SA/Dx5 cells overexpressing MDR1 after 72 hrs by alamar blue assay, IC50=33 nM 21341674
human A2780 cells Cytotoxic assay 72 h Cytotoxicity against human A2780 cells after 72 hrs by MTT assay, IC50=33 nM 24900725
human MDA-MB-435 cells Cytotoxic assay 72 h Cytotoxicity against human MDA-MB-435 cells incubated for 72 hrs by MTT assay, GI50=34 nM 22867019
human stomach cancer cell line (MKN45) Cytotoxic assay In Vitro cytotoxicity against human stomach cancer cell line (MKN45), IC50=38 nM 11334569
human KB3-1 cells Cytotoxic assay Cytotoxicity against human KB3-1 cells after MTT assay, IC50=40 nM 18829334
mouse P388 cells Cytotoxic assay Cytotoxicity against mouse P388 cells after MTT assay, IC50=45 nM 18829334
A427 human lung carcinoma Proliferation assay Antiproliferative activity measured against A427 human lung carcinoma, IC50=49 nM 9876111
human U251 cells Function assay 6-24 h Inhibition of topoisomerase-1 in human U251 cells assessed as inhibition of hypoxia-induced HIF-1alpha accumulation in nuclear extract after 6 to 24 hrs by immunoblot analysis, EC50=54 nM 22305612
human colon cancer cell line (WiDr) Cytotoxic assay In Vitro cytotoxicity against human colon cancer cell line (WiDr), IC50=56 nM 11334569
human HepG2 cells Cytotoxic assay 4 days Cytotoxicity against human HepG2 cells after 4 days by MTT assay, IC50=60 nM 18554906
human KB cells Cytotoxic assay 72 h Cytotoxicity against human KB cells after 72 hrs sulforhodamine B colorimetric assay, IC50=62.5 nM 25008456
human HCT8 cells Cytotoxic assay 3 days Cytotoxicity against human HCT8 cells after 3 days by MTT assay, IC50=70 nM 20392545
human GBM2 cells Proliferation assay 72 h Antiproliferative activity against human GBM2 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method, IC50=0.13 μM 26355532
SK-MEL-2 cells Cytotoxic assay 72 h Cytotoxicity against human SK-MEL-2 cells after 72 hrs by alamar blue assay, IC50=0.14 μM 21341674
human IGROV1 cells Cytotoxic assay 72 h Cytotoxicity against human IGROV1 cells after 72 hrs by alamar blue assay, IC50=0.16 μM 21341674
human U87 cells Proliferation assay 48 h Antiproliferative activity against human U87 cells assessed as growth inhibition after 48 hrs by MTT assay, IC50=0.16 μM 24826818
human HT1080 cells Proliferation assay 48 h Antiproliferative activity against human HT1080 cells assessed as growth inhibition incubated for 48 hrs by sulforhodamine B assay, IC50=0.18 μM 26408815
human Hep3B cells Proliferation assay 72 h Antiproliferative activity against human Hep3B cells after 72 hrs by XTT assay, GI50=0.22 μM 19796956
human GBM3 cells Proliferation assay 72 h Antiproliferative activity against human GBM3 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method, IC50=0.38 μM 26355532
human KBVIN cells Cytotoxic assay 72 h Cytotoxicity against human KBVIN cells after 72 hrs by SRB assay, IC50=0.4 μM 25438769
human GBM1 cells Proliferation assay 72 h Antiproliferative activity against human GBM1 cells assessed as reduction in cell viability incubated for 72 hrs by WST-1 method, IC50=0.46 μM 26355532
human U937 cells Cytotoxic assay 48 h Cytotoxicity against human U937 cells expressing p53 mutant after 48 hrs by SRB assay ， IC50=1.1 μM 19715319
Caco2 Cytotoxicity assay 24 hrs Cytotoxicity against human Caco2 cells after 24 hrs by MTT assay, IC50=0.119μM. 24980118
Jurkat Cytotoxicity assay 24 hrs Cytotoxicity against human Jurkat cells after 24 hrs by MTT assay, IC50=0.127μM. 24980118
A375 Cytotoxicity assay 24 hrs Cytotoxicity against human A375 cells after 24 hrs by MTT assay, IC50=0.162μM. 24980118
HeLa Cytotoxicity assay 24 hrs Cytotoxicity against human HeLa cells after 24 hrs by MTT assay, IC50=0.38μM. 24980118
MDA-MB-231 Cytotoxicity assay 24 hrs Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay, IC50=0.473μM. 24980118
NCI-H460 Antiproliferative assay 1 hr Antiproliferative activity against human NCI-H460 cells after short term exposure for 1 hr measured after 72 hrs in drug-free medium, IC50=0.61μM. 19530720
HCT8 Antiproliferative assay 48 hrs Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay, IC50=1.875μM. 25481395
KB Antiproliferative assay 48 hrs Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay, IC50=2.282μM. 25481395
SGC7901 Antiproliferative assay 48 hrs Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay, IC50=2.292μM. 25481395
HepG2 Antiproliferative assay 48 hrs Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay, IC50=4.208μM. 25481395
MDA-MB-231 Apoptosis assay Induction of apoptosis in human MDA-MB-231 cells assessed as p53 phosphorylation at Ser15 by Western blotting analysis 24980118
HeLa Apoptosis assay 0.8 to 1.6 uM 24 hrs Induction of apoptosis in human HeLa cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA 24980118
MDA-MB-231 Apoptosis assay 0.8 to 1.6 uM 24 hrs Induction of apoptosis in human MDA-MB-231 cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA 24980118
A375 Apoptosis assay 0.8 to 1.6 uM 24 hrs Induction of apoptosis in human A375 cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA 24980118
Caco2 Apoptosis assay 0.8 to 1.6 uM 24 hrs Induction of apoptosis in human Caco2 cells assessed as inhibition of DNA synthesis at 0.8 to 1.6 uM after 24 hrs by BrdU staining-based ELISA 24980118
A375 Apoptosis assay Induction of apoptosis in human A375 cells assessed as p53 phosphorylation at Ser15 by Western blotting analysis 24980118
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells 29435139
Daoy qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells 29435139
Klicken Sie hier, um weitere experimentelle Daten zu Zelllinien anzuzeigen

Chemische Informationen, Lagerung & Stabilität (Chemical Information, Storage & Stability)

Molekulargewicht 457.91 Formel

C23H23N3O5.HCl

 Lagerung (Ab dem Eingangsdatum)
CAS-Nr. 119413-54-6 SDF herunterladen Lagerung von Stammlösungen

Synonyme Nogitecan HCl, SKFS 104864A, NSC 609699 Smiles CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl

Löslichkeit (Solubility)

In vitro
Charge:

DMSO : 91 mg/mL (198.72 mM)
(Feuchtigkeitskontaminiertes DMSO kann die Löslichkeit verringern. Verwenden Sie frisches, wasserfreies DMSO.)

Water : 91 mg/mL

Ethanol : Insoluble

Molaritätsrechner

Masse Konzentration Volumen Molekulargewicht
Verdünnungsrechner Molekulargewichtsrechner

In vivo
Charge:

In-vivo-Formulierungsrechner (Klare Lösung)

Schritt 1: Geben Sie die untenstehenden Informationen ein (Empfohlen: Ein zusätzliches Tier zur Berücksichtigung von Verlusten während des Experiments)

mg/kg g μL

Schritt 2: Geben Sie die In-vivo-Formulierung ein (Dies ist nur der Rechner, keine Formulierung. Bitte kontaktieren Sie uns zuerst, wenn es im Abschnitt "Löslichkeit" keine In-vivo-Formulierung gibt.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Berechnungsergebnisse:

Arbeitskonzentration: mg/ml;

Methode zur Herstellung der DMSO-Stammlösung: mg Wirkstoff vorgelöst in μL DMSO ( Konzentration der Stammlösung mg/mL, Bitte kontaktieren Sie uns zuerst, wenn die Konzentration die DMSO-Löslichkeit der Wirkstoffcharge überschreitet. )

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügenμL PEG300, mischen und klären, dann hinzufügenμL Tween 80, mischen und klären, dann hinzufügen μL ddH2O, mischen und klären.

Methode zur Herstellung der In-vivo-Formulierung: Nehmen Sie μL DMSO Stammlösung, dann hinzufügen μL Maisöl, mischen und klären.

Hinweis: 1. Bitte stellen Sie sicher, dass die Flüssigkeit klar ist, bevor Sie das nächste Lösungsmittel hinzufügen.
2. Achten Sie darauf, das/die Lösungsmittel der Reihe nach hinzuzufügen. Sie müssen sicherstellen, dass die bei der vorherigen Zugabe erhaltene Lösung eine klare Lösung ist, bevor Sie mit der Zugabe des nächsten Lösungsmittels fortfahren. Physikalische Methoden wie Vortex, Ultraschall oder ein heißes Wasserbad können zur Unterstützung des Lösens verwendet werden.

Wirkmechanismus (Mechanism of Action)

Merkmale
Topotecan is a water-soluble derivative of camptothecin.
Targets/IC50/Ki
Topo I (DU-145 Luc cells)
(Cell-free assay)
2 nM
Topo I (MCF-7 Luc cells)
(Cell-free assay)
13 nM
In vitro

Stronger drug activity of Topotecan HCl is observed for DU-145 Luc and MCF-7 Luc cells. This compound causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. It stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion.

In vivo

Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan HCl demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for this compound-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and this chemical-treated mice inoculated i.p. with MCF-7 Luc cells. This compound elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. It markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. Gliomas preferentially express TRAIL R2 and that treatment with this chemical significantly up-regulates its expression.

Literatur
  • [4] https://pubmed.ncbi.nlm.nih.gov/22689924/
  • [5] https://pubmed.ncbi.nlm.nih.gov/9523734/

Anwendungen (Applications)

Methoden Biomarker Bilder PMID
Western blot LC3 / p62 p53 / sesn2 / p-AMPK
S1231-WB1
23024792
Growth inhibition assay Cell viability
S1231-viability1
28544814

Klinische Studieninformationen (Clinical Trial Information)

(Daten von https://clinicaltrials.gov, aktualisiert am 2024-05-22)

NCT-Nummer Rekrutierung Erkrankungen Sponsor/Kooperationspartner Startdatum Phasen
NCT04455139 Terminated
Eye Cancer Retinoblastoma
Prof. Beck Popovic Maja|University of Lausanne Hospitals
 November 15 2021 Phase 2
NCT05083000 Unknown status
COVID-19 Respiratory Infection
National University Hospital Singapore|Christian Medical College Vellore India
 August 16 2021 Phase 1
NCT04156347 Active not recruiting
Retinoblastoma
Targeted Therapy Technologies LLC
 June 16 2021 Phase 1
NCT04428879 Recruiting
Retinoblastoma
The Hospital for Sick Children
 June 16 2020 Phase 1

Häufig gestellte Fragen (Frequently Asked Questions)

Frage 1:
I would like to get it for mice intraperitoneally injection. What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

Antwort:
It is generally prepared by Saline for I.P. administration.